<DOC>
	<DOCNO>NCT01452308</DOCNO>
	<brief_summary>This study evaluate safety tolerability simtuzumab ( GS-6624 ) patient fibrosis liver . Up 20 participant enrol two sequential cohort . Cohort 1 consist 10 participant receive simtuzumab every week total 3 infusion . Participants Cohort 2 ( 10 subject ) also receive simtuzumab every week total 3 infusion ; dose depend safety tolerability simtuzumab see Cohort 1 . Participants cohort complete main study allow continue simtuzumab treatment additional extension period , receive 13 additional infusion simtuzumab fix dose 700 mg additional 24 week .</brief_summary>
	<brief_title>Pilot Study Simtuzumab Treatment Liver Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Males females 18 65 year age Chronic liver disease etiology Stage 13 fibrosis Metavir score liver biopsy . Body mass index &lt; 36 kg/m2 Any evidence hepatic decompensation past present Subjects currently abuse amphetamine , cocaine , opiates , alcohol Clinically significant cardiac disease History cancer , nonmelanomatous skin cancer , within 5 year prior Screening Systemic fungal , bacterial , viral , infection control Use systemic immunosuppressant within 28 day Pretreatment Phase Use approve therapy hepatitis C hepatitis B virus within 28 day Pretreatment Phase Pregnant lactate History bleed diathesis within last 6 month study Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Gilead</keyword>
	<keyword>Gilead Sciences</keyword>
	<keyword>GSI</keyword>
	<keyword>Liver Fibrosis</keyword>
	<keyword>Liver</keyword>
	<keyword>Fibrosis</keyword>
</DOC>